Table 3. Comparison of clinicopathological features of DLBCL-IV, IVLBCL, and DLBCL-noIV.
| DLBCL-IV (n=11) | IVLBCL (n=11) | DLBCL-noIV (n=15) | P-value | |||
|---|---|---|---|---|---|---|
| DLBCL-IV vs. IVLBCL |
DLBCL-IV vs. DLBCL-noIV | IVLBCL vs. DLBCL-noIV | ||||
| Age [years; median (range)] | 74 (62-83) | 75 (58-91) | 69 (43-86) | 0.998 | 0.495 | 0.458 |
| Sex, male [n (%)] | 5 (46) | 5 (46) | 7 (47) | 1.000 | 1.000 | 1.000 |
| Disturbance of consciousness [n (%)] | 5 (46) | 3 (27) | 1 (6.7) | 0.659 | 0.054 | 0.279 |
| Hepatomegaly [n (%)] | 3 (27) | 2 (18) | 1/12 (8.3) | 1.000 | 0.950 | 1.000 |
| Splenomegaly [n (%)] | 7 (64) | 3 (27) | 0/12 (0.0) | 0.198 | 0.004* | 0.186 |
| Hemophagocytosis [n (%)] | 8/10 (80) | 5/9 (56) | 1/7 (14) | 0.350 | 0.046* | 0.290 |
| Peripheral blood involvement [n (%)] | 1 (9.1) | 2 (18) | 0 (0.0) | 1.000 | 0.846 | 0.508 |
| Ann Arbor stage III/IV [n (%)] | 11 (100) | 10 (91) | 5 (33) | 1.000 | 0.002* | 0.010* |
| WBC [×102/μl; median (range)] | 59 (29-128) | 58 (21-110) | 66 (23-132) | 0.984 | 0.818 | 0.713 |
| Hb [g/dl; median (range)] | 9.7 (6.3-12.9) | 10 (7.5-15.6) | 11.6 (8.1-14.3) | 0.958 | 0.110 | 0.193 |
| PLT [×104/μl; median (range)] | 8.2 (1.8-27.1) | 14.1 (1.2-29.6) | 28.6 (11.1-57.9) | 0.413 | <0.001* | 0.005* |
| LD [U/l; median (range)] | 781 (261-2,018) | 867 (244-1,862) | 355 (142-953) | 0.885 | 0.046* | 0.014* |
| Ferritin [ng/ml; median (range)] | 6,506 (360-29,070) | 477 (287-759) | 159 (11.2-284) | 0.006* | 0.003* | 0.002* |
| sIL-2R [U/ml; median (range)] | 8,768 (469-37,583) | 4,633 (412-18,832) | 3,752 (225-4,180) | 0.566 | 0.396 | 0.971 |
| CD5-positive [n (%)] | 5 (46) | 6/8 (75) | 0 (0.0) | 0.352 | 0.014* | 0.001* |
| CD10-positive [n (%)] | 2 (18) | 1/8 (13) | 6 (40) | 1.000 | 0.789 | 1.000 |
| Bcl-2-positive [n (%)] | 10 (91) | 8/8 (100) | 14 (93) | 1.000 | 1.000 | 1.000 |
| Bcl-6-positive [n (%)] | 5 (46) | 5/8 (63) | 13 (87) | 0.650 | 0.115 | 0.594 |
| IRF4/MUM-1-positive [n (%)] | 9 (82) | 8/8 (100) | 12 (80) | 1.000 | 1.000 | 1.000 |
| CD29-positive [n (%)] | 2 (18) | 0/8 (0.0) | 7 (47) | 0.485 | 0.433 | 0.156 |
| CD54-positive [n (%)] | 4 (36) | 3/8 (38) | 10 (67) | 1.000 | 0.466 | 0.664 |
| Ki-67 labeling index [%; median (range)] | 62 (40-93) | 79.3 (60-100) | 67 (40-98) | 0.131 | 0.770 | 0.277 |
| PD-L1-positive [n (%)] | 6 (55) | 2/8 (25) | 10 (67) | 0.704 | 0.689 | 0.268 |
| PD-L1 score [median (range)] | 0.82 (0-2) | 0.25 (0-1) | 0.8 (0-2) | 0.211 | 0.998 | 0.195 |
Abbreviations: DLBCL-IV, diffuse large B-cell lymphoma with significant intravascular invasion; DLBCL-noIV, DLBCL with no significant intravascular invasion; Hb, hemoglobin; IVLBCL, intravascular large B-cell lymphoma; LD, lactate dehydrogenase; M, male; NE, not examined; PD-L1, programmed death-ligand 1; PLT, platelet; sIL2R, soluble interleukin 2 receptor; WBC, white blood cell; vs., versus.
*P-value < 0.05